ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "rheumatoid arthritis (RA) and tumor necrosis factor (TNF)"

  • Abstract Number: 1096 • 2015 ACR/ARHP Annual Meeting

    B Cells Are Prime Producers of Tumor Necrosis Factor Alpha in Rheumatoid Arthritis

    Victor Wang1, Nida Meednu1, Wen Sun2, Javier Rangel-Moreno3, Lianping Xing2 and Jennifer H. Anolik1, 1Medicine- Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, NY, 2Pathology & Lab Medicine, University of Rochester Medical Center, Rochester, NY, 3Medicine- Allergy, Immunology, and Rheumatology, University of Rochester Medical Center, Rochester, NY

    Background/Purpose: Rheumatoid arthritis (RA) is a systemic autoimmune disease, which causes joint inflammation and bone loss. Inflammation-mediated joint damage is linked to the imbalance of…
  • Abstract Number: 1364 • 2015 ACR/ARHP Annual Meeting

    Treating Experimental Arthritis with the Innate Immune Inhibitor IL-37 Reduces Joint and Systemic Inflammation

    Giulio Cavalli1, Marije Koenders2, Lorenzo Dagna3, Alberto Mantovani4, Cecilia Garlanda4, Leo Joosten5 and Charles Dinarello1, 1Department of Medicine, Division of Infectious Diseases, University of Colorado, Denver, CO, 2Experimental Rheumatology, Radboud university medical center, Nijmegen, Netherlands, 3Internal Medicine and Clinical Immunology, Vita-Salute San Raffaele University, Milano, Italy, 4Research Institute Humanitas, Milan, Italy, 5Internal Medicine, Radboud university medical center, Nijmegen, Netherlands

    Background/Purpose: Characterized as a fundamental inhibitor of innate inflammation, IL‑1 family member IL‑37 is expressed in the synovia of patients with rheumatoid arthritis. We investigated…
  • Abstract Number: 1521 • 2015 ACR/ARHP Annual Meeting

    Screening for Urinary Tract Infection in Rheumatoid Arthritis Patients Treated with TNF-Inhibitors in the Daily Clinic

    Renata Baronaite Hansen1, Anne Brun Hesselvig2, Rolf Magnus Arpi2, Eva Kristin Jonassen1, Gunhild Bukh1 and Ole Rintek Madsen1, 1Department of Rheumatology/C, Department of Rheumatology/C, Copenhagen University Hospital Gentofte, Hellerup, Denmark, 2Department of Clinical Microbiology, Department of Clinical Microbiology, Copenhagen University Hospital Herlev, Herlev, Denmark

    Background/Purpose: Patients with rheumatoid arthritis (RA) treated with biologic agents are at increased risk of infection. Therefore, screening for urinary tract infection (UTI) with urine…
  • Abstract Number: 1629 • 2015 ACR/ARHP Annual Meeting

    Non-Interventional Clinical Study Investigating the Use of Golimumab in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis in Germany – 3rd Interim Analysis

    Matthias H. Thomas1, Klaus Krüger2, Pee Aries3, Martin Bohl-Buehler4, Jan Brandt-Juergens5, Verena Rickert6 and Siegfried Wassenberg7, 1Medical Affairs, MSD Sharp & Dohme GmbH, Bünde, Germany, 2Praxiszentrum St. Bonifatius, München, Germany, 3Rheumatologie im Struenseehaus, Hamburg, Germany, 4Friedrich-Ebert-Str. 35, Rheumahaus, Potsdam, Germany, 5Praxis Brandt-Juergens/Karberg, Berlin, Germany, 6Medical Affairs, MSD Sharp&Dohme GmbH, Haar, Germany, 7Fachkrankenhaus, Ratingen, Germany

    Background/Purpose: Golimumab (GOL) has shown its efficacy and safety in various randomized clinical trials with accurately selected patients. Data from daily clinical practice in Germany…
  • Abstract Number: 1677 • 2015 ACR/ARHP Annual Meeting

    Disease-Regulated Expression of Anti-Inflammatory Interleukin-10 for the Treatment of Rheumatoid Arthritis

    Mathijs G.A. Broeren1, Miranda B. Bennink1, Onno J. Arntz2, Wim van den Berg2 and Fons A.J. van de Loo2, 1Experimental Rheumatology, Radboud university medical center, Nijmegen, The Netherlands, Nijmegen, Netherlands, 2Experimental Rheumatology, Radboud university medical center, Nijmegen, Netherlands

    Background/Purpose: The current treatment for patients with rheumatoid arthritis (RA) consists of biological drugs, often in combination with methotrexate. However, some patients fail to respond…
  • Abstract Number: 2581 • 2015 ACR/ARHP Annual Meeting

    TNF-Alpha Receptor II Signaling Plays an Important Role in Maintaining the Expression of Forkhead Box P3 in Murine Regulatory T Cells

    Wen-Yi Tseng1,2, Kay McNamee1, Adam Cribbs3, Anviti Vyas1 and Richard O. Williams1, 1Kennedy Institute of Rheumatology, University of Oxford, Oxford, United Kingdom, 2Division of Rheumatology, Allergy and Immunology, Chang Gung Memorial Hospital at Keelung, Keelung, Taiwan, 3Computational Genomics and Training Centre, MRC Functional Genomics Unit, University of Oxford, Oxford, United Kingdom

    Background/Purpose: TNF-α is a key regulator of inflammation, which induces signal transduction by binding to two structurally and functionally distinct receptors on target cells: TNF…
  • Abstract Number: 2464 • 2014 ACR/ARHP Annual Meeting

    Anti-Arthritic Effect of Tubastatin A, a Novel Histone Deacetylases-6 Inhibitor, Is Mediated By Stabilization of IkB Via Suppression of Ubiquitin-Proteasome Pathway

    Eun Chung Hong1, Hemin Jeong2, Jiwon Hwang2, Eun-Kyung Bae1, Hyungjin Kim2, Joong Kyong Ahn3, Hoon-Suk Cha2, Eun-mi Koh4 and Jaejoon Lee4, 1Samsung Biomedical Research Institute, Seoul, South Korea, 2Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, 3Sungkyunkwan univ. school of medicine, Seoul, South Korea, 4Division of Rheumatology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea

    Background/Purpose: Histone deacetylase-6 (HDAC-6) functions as a non-epigenetic deacetylase for non-histone substrates and regulates microtubule-mediates processes such as cell migration, cell cycle arrest, and angiogenesis.…
  • Abstract Number: 2369 • 2014 ACR/ARHP Annual Meeting

    Management of Perioperative Tumor Necrosis -á Inhibitors in Rheumatoid Arthritis Undergoing Arthroplasty: A Systematic Review and Meta-Analysis

    Susan M. Goodman1, Indu Menon2, Rie Smethurst3, Paul Christos4 and Vivian P. Bykerk1, 1Rheumatology, Hospital for Special Surgery, New York, NY, 2Rheumatology, Hospital for Special Surgery, NY, NY, 3Education - Academic Training, Hospital for Special Surgery, NY, NY, 4Healthcare Policy and Research, Weill Cornell Medical College, NY, NY

    Background/Purpose: Tumor Necrosis Factor α inhibitors (TNFi) are widely used in patients with RA (Rheumatoid Arthritis) undergoing orthopedic surgery, yet its optimal perioperative management is…
  • Abstract Number: 2370 • 2014 ACR/ARHP Annual Meeting

    Management of Perioperative Tumor Necrosis Factor α Inhibitors in Rheumatoid Arthritis Undergoing Arthroplasty: A Systematic Review and Meta-Analysis

    Susan M. Goodman1, Indu Menon2, Rie Smethurst3, Paul Christos4 and Vivian P. Bykerk1, 1Rheumatology, Hospital for Special Surgery, New York, NY, 2Rheumatology, Hospital for Special Surgery, NY, NY, 3Education - Academic Training, Hospital for Special Surgery, NY, NY, 4Healthcare Policy and Research, Weill Cornell Medical College, NY, NY

    Background/Purpose: Tumor Necrosis Factor α inhibitors (TNFi) are widely used in patients with RA (Rheumatoid Arthritis) undergoing orthopedic surgery, yet its optimal perioperative management is…
  • Abstract Number: 1909 • 2014 ACR/ARHP Annual Meeting

    Incidence of Congestive Heart Failure in Subjects with Rheumatoid Arthritis Receiving Anti-Tumour Necrosis Factor Drugs: Results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis

    Alper van Sijl1, Mamas Mamas2, Mark Lunt3,4, . BSRBR Control Centre Consortium3, Kath Watson5, Deborah P. Symmons3,6 and Kimme L. Hyrich7, 1Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Manchester Academic Health Science Centre, University of Manchester, Manchester, United Kingdom, 2Manchester Heart Centre, Manchester Royal Infirmary, Oxford Road, Manchester, UK; Institute of Cardiovascular Sciences, University of Manchester, Manchester, United Kingdom, 3Arthritis Research UK Centre for Epidemiology, University of Manchester, Manchester, United Kingdom, 4Arthritis Research UK Centre for Epidemiology, Manchester Academic Health Science Centre, University of Manchester, Manchester, United Kingdom, 5Arthritis Research UK Epidemiology Unit, Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, United Kingdom, 6Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester, United Kingdom, 7Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom

    Background/Purpose Subjects with rheumatoid arthritis (RA) are at a higher risk of developing cardiovascular (CV) disease compared to the general population, with an increased incidence…
  • Abstract Number: 846 • 2014 ACR/ARHP Annual Meeting

    Rheumatoid Arthritis, Anti-Tumor Necrosis Factor Therapy, and Risk of Squamous Cell and Basal Cell Skin Cancer- a Nationwide Population Based Prospective Cohort Study from Sweden

    Pauline Raaschou1, Julia F Simard2, Charlotte Asker-Hagelberg3, Johan Askling4 and the ARTIS Study group5, 1Karolinska Institutet, Stockholm, Sweden, 2Division of Epidemiology, Health Research and Policy Department, and Division of Immunology & Rheumatology, Department of Medicine, Stanford School of Medicine, Stanford, CA, 3Swedish Medical Products Agency, SE-751 03 Uppsala, Sweden, 4Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, 5Karolinska Institutet och Svensk Reumatologisk förening, Solna, Sweden

    Background/Purpose: There is a concern that tumor necrosis factor inhibitors (TNFi) may interplay with tumor biology and increase the risk of cancer, in particular cancer…
  • Abstract Number: 484 • 2014 ACR/ARHP Annual Meeting

    Reactivation of Hepatitis B Virus in Patients with Rheumatoid Arthritis after Anti-TNF Therapy

    Seung Min Jung1, Hong Ki Min1, Jung Hee Koh1, Jin Young Kang1, Jennifer Lee1, Seung-Ki Kwok2, Ji Hyeon Ju1, Hyeok-Jae Ko3, Kyung-Su Park4, Ho-Youn Kim1 and Sung-Hwan Park1, 1Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea, 2Division of Rheumatology, Department of Internal Medicine, St. Mary’s hospital, The Catholic University of Korea, Seoul, South Korea, 3Division of Rheumatology, Department of Internal Medicine, Daejeon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Daejeon, South Korea, 4Internal Medicine, St. Vincent Hospital, SuWon Gyeonggi-do, South Korea

    Background/Purpose: Anti-TNF therapy was known to increase the risk of certain infection. There are only limited data about the reactivation of hepatitis B virus (HBV)…
  • Abstract Number: 1000 • 2013 ACR/ARHP Annual Meeting

    Comparison Of The Cost-Effectiveness Of The Treatment Strategies With and Without Biological Response Modifiers For Patients With Recently Diagnosed Rheumatoid Arthritis Following A Clinical Guideline For Treatment Selection

    An Tran-Duy1, Annelies Boonen2, Wietske Kievit3, Piet L.C.M. van Riel4, Mart A.F.J. van de Laar5 and Johan L. Severens6, 1Department of Internal Medicine, Maastricht University Medical Center, Maastricht, Netherlands, 2Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, 3Department of Rheumatology and DREAM registry, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 4Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 5Rheumatology, Medisch Spectrum Twente & University of Twente, Enschede, Netherlands, 6Institute of Health Policy and Management, Erasmus University Rotterdam, Rotterdam, Netherlands

    Background/Purpose: In clinical practice, management of rheumatoid arthritis (RA) is characterized by a sequence of drugs which is determined based on patient characteristics, notably disease…
  • Abstract Number: 804 • 2013 ACR/ARHP Annual Meeting

    Tumour Necrosis Factor Inhibitors and The Risk Of Acute Coronary Syndrome In Rheumatoid Arthritis – a National Cohort Study

    Lotta Ljung1,2, Johan Askling3, Solbritt M. Rantapää-Dahlqvist4, Lennart T.H. Jacobsson5 and The ARTIS Study Group6, 1Clinical epidemiology unit, Karolinska Institutet, Stockholm, Sweden, 2Department for Public Health and Clinical Medicine/Rheumatology, Umeå University, Umeå, Sweden, 3Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, 4Department for Public Health and Clinical Medicine/ Rheumatology, Umeå University, Umeå, Sweden, 5Department of Rheumatology and Inflammation Research, Institute of Medicine, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, 6Karolinska Institutet, Stockholm, Sweden

    Background/Purpose: The high risk of ischemic heart disease (IHD) in patients with rheumatoid arthritis (RA) has been linked to inflammation and disease severity. Treatment with…
  • Abstract Number: 805 • 2013 ACR/ARHP Annual Meeting

    Good Response On Tumour Necrosis Factor Inhibitors Are Associated With a Decreased Risk Of Acute Coronary Syndromes In Patients With Rheumatoid Arthritis

    Lotta Ljung1,2, Lennart T.H. Jacobsson3, Solbritt M. Rantapää-Dahlqvist4, Johan Askling5 and The ARTIS Study Group6, 1Clinical epidemiology unit, Karolinska Institutet, Stockholm, Sweden, 2Department for Public Health and Clinical Medicine/Rheumatology, Umeå University, Umeå, Sweden, 3Department of Rheumatology and Inflammation Research, Institute of Medicine, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, 4Department for Public Health and Clinical Medicine/ Rheumatology, Umeå University, Umeå, Sweden, 5Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, 6Karolinska Institutet, Stockholm, Sweden

    Background/Purpose: Inflammatory activity, as well as traditional cardiovascular risk factors, have been suggested to underlie the increased risk of coronary disease in patients with rheumatoid…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology